Plain-English translation of NCT06317649 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding to a two-drug combination of and works better than using just and alone for older adults or those too frail for intensive chemotherapy who have been newly diagnosed with acute myeloid leukemia with a specific FLT3 mutation. The trial will compare how many patients achieve remission (where cancer is no longer detectable) with each treatment approach. Your doctors will monitor your response closely through blood tests and bone marrow samples.
Acute myeloid leukemia is a serious blood cancer, and older or frail patients cannot always tolerate the strongest chemotherapy treatments. This trial is exploring whether adding a targeted drug () to an existing gentler treatment might help more patients achieve and maintain remission.
You likely qualify if…
You likely don't qualify if…
You will receive treatment in two phases: an induction phase (up to 2 months) where you take medication daily to try to bring your leukemia into remission, followed by a consolidation phase (up to 2 years) where you continue taking the medications to keep the cancer under control. Each treatment cycle lasts 28 days, and you will have regular blood tests and bone marrow biopsies to monitor how well the treatment is working. Your doctors will also track the level of your leukemia mutation using sensitive genetic testing.
AI-generated summary from trial data · Jul 22, 2026 · Not medical advice
United States